CellSight Technologies, Inc.

A Study Using [18F]F AraG PET to Evaluate Response to Checkpoint Inhibitor Therapy(CkIT) in Patients With Solid Tumors

Role: lead

Detection of Graft Versus Host Disease With [18F]F-AraG

Role: lead

[18F]-AraG PET Imaging in LA HNSCC

Role: collaborator

[18F]F-AraG/Total Body PET Imaging and Healthy Subjects and Lung Cancer Patients

Role: collaborator

18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma

Role: collaborator

Imaging Immune Activation in COVID-19

Role: lead

Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

Role: lead

Test-retest Evaluation of [18F]F-AraG PET

Role: lead

Imaging Immune Activation in HIV by PET-MR

Role: lead

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab

Role: collaborator

PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)

Role: collaborator

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Role: lead

Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Role: lead

[18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy

Role: lead

Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer

Role: collaborator

[18F]-AraG for the Detection of T-Cell Activation in Advanced Non-small Cell Lung Cancer Patients Undergoing PD-1/PD-L1-Directed Therapy

Role: collaborator

Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1

Role: collaborator

T-Cell PET Imaging With [18F]F-AraG in Lung Cancer

Role: collaborator

Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans

Role: lead